Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LYRA | US
-0.01
-3.08%
Healthcare
Biotechnology
30/06/2024
17/10/2024
0.23
0.24
0.24
0.23
Lyra Therapeutics Inc. a clinical-stage biotechnology company focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear nose and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210 an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS) which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical Inc. and changed its name to Lyra Therapeutics Inc. in July 2018. Lyra Therapeutics Inc. was incorporated in 2005 and is headquartered in Watertown Massachusetts.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
57.7%1 month
67.7%3 months
71.9%6 months
142.4%-
-
0.49
1.19
0.39
0.66
153.77
-
-74.33M
15.24M
15.24M
-
-2.98K
-
30.60
-156.52
4.28
5.44
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.03
Range1M
0.08
Range3M
0.13
Rel. volume
0.51
Price X volume
70.45K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
IN8bio Inc. Common Stock | INAB | Biotechnology | 0.2301 | 16.69M | 0.52% | n/a | 43.30% |
Synlogic Inc | SYBX | Biotechnology | 1.42 | 16.61M | -1.39% | n/a | 0.00% |
Can-Fite BioPharma Ltd | CANF | Biotechnology | 2.7 | 16.46M | 0.00% | n/a | 0.64% |
Evaxion Biotech A/S | EVAX | Biotechnology | 2.71 | 15.99M | 0.00% | n/a | 837.11% |
Indaptus Therapeutics Inc. Common Stock | INDP | Biotechnology | 1.55 | 15.81M | 8.39% | n/a | 2.12% |
Orgenesis Inc | ORGS | Biotechnology | 3.238 | 15.45M | -4.48% | n/a | -84.02% |
ImmunoPrecise Antibodies Ltd | IPA | Biotechnology | 0.539 | 15.10M | -3.94% | n/a | 49.00% |
Cara Therapeutics Inc | CARA | Biotechnology | 0.2668 | 15.07M | 0.68% | n/a | 406.66% |
IMNN | IMNN | Biotechnology | 0.9787 | 14.09M | -2.12% | n/a | 37.13% |
Aytu BioScience Inc | AYTU | Biotechnology | 2.29 | 14.08M | 0.11% | n/a | 54.59% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.54 | 0 | -1.56% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.66 | 0.53 | Expensive |
Ent. to Revenue | 153.77 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 0.49 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 71.94 | 72.92 | Par |
Debt to Equity | 1.19 | -1.24 | Expensive |
Debt to Assets | 0.39 | 0.25 | Expensive |
Market Cap | 15.24M | 3.78B | Emerging |